Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor

Imatinib mesylate, as treatment for gastrointestinal stromal tumors (GIST), has dramatically changed the prognosis for survival – not only because it is efficacious, but also because it attracted attention to this malignant disease. GIST is now a well-known disease entity and a paradigm for targeted...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameron, Silke, Schaefer, Inga-Marie, Schwoerer, Harald, Ramadori, Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published: October, 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220906/
https://www.ncbi.nlm.nih.gov/pubmed/22114577
http://dx.doi.org/10.1159/000333471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220906/
https://www.ncbi.nlm.nih.gov/pubmed/22114577
http://dx.doi.org/10.1159/000333471

Ejemplares similares